Seizures clinical trials at UC Irvine

3 in progress, 2 open to eligible people

Showing trials for

  • XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

    open to eligible people ages 18 years and up

    The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.

    Orange, California and other locations

  • XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    open to eligible people ages 12 years and up

    This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).

    Orange, California and other locations

  • of XEN1101 in Epilepsy

    Sorry, accepting new patients by invitation only

    This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of seizures for up to 3 years.

    Orange, California and other locations

Last updated: